Latecomer Amgen takes ‘platform approach’ in obesity as PhII data loom

As Am­gen catch­es up with lead­ers in the bur­geon­ing obe­si­ty space, it’s un­der­scor­ing a “plat­form ap­proach” and shoot­ing for “broad op­tion­al­i­ty” in the de­sign of its Phase III.

Speak­ing at the Bank of Amer­i­ca Mer­rill Lynch Glob­al Health­care Con­fer­ence, Am­gen CFO Pe­ter Grif­fith spot­light­ed two of its obe­si­ty pro­grams: AMG 133, a Phase II pro­gram that’s been named maride­bart cafraglu­tide, or mari; and the Phase I can­di­date AMG 786. Mari is “en­rolling well,” he not­ed; the study is ten­ta­tive­ly set to read out in late 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.